SCHEMBL2403253

SCHEMBL2403253

CC(C)N1CCN(C(=O)C2CCC(NS(=O)(=O)c3ccccc3C#N)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.53
DRD2 P14416 1/20 0.50
ADRA1D P25100 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50
HRH2 P25021 1/20 0.46
HRH1 P35367 1/20 0.46
CCR8 P51685 2/20 0.43
ALDH1A1 P00352 1/20 0.42
NR1H2 P55055 1/20 0.41
MC4R P32245 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HRH3 Q9Y5N1 4/20 0.39
SOS1 Q07889 1/20 0.39
SFRP1 Q8N474 1/20 0.38
MMP2 P08253 1/20 0.38
MMP13 P45452 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403245 1.00 ATM (0.53) ATMDRD2ADRA1DADRA1AADRA1B
SCHEMBL2403258 0.85 ALDH1A1 (0.53) DRD2ADRA1DADRA1AADRA1BHRH2
SCHEMBL2405226 0.85 ALDH1A1 (0.53) DRD2ADRA1DADRA1AADRA1BHRH2
SCHEMBL2403265 0.85 ALDH1A1 (0.53) DRD2ADRA1DADRA1AADRA1BHRH2
SCHEMBL2401720 0.85 CCR8 (0.52) HRH2HRH1CCR8ALDH1A1HRH3
SCHEMBL2401724 0.85 CCR8 (0.52) HRH2HRH1CCR8ALDH1A1HRH3
SCHEMBL2401730 0.85 DRD2 (0.48) DRD2ADRA1DADRA1AADRA1BHRH2
SCHEMBL2401728 0.85 DRD2 (0.48) DRD2ADRA1DADRA1AADRA1BHRH2
SCHEMBL2401780 0.84 ATM (0.56) ATMDRD2ADRA1DADRA1AADRA1B
SCHEMBL2401777 0.84 ATM (0.56) ATMDRD2ADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017773-B2 Cyclohexyl sulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-13 US disclosed
EP-1979322-B1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2010-09-01 EP disclosed
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES NETTEKOVEN MATTHIAS 2010-05-13 US disclosed
EP-1979322-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2008-10-15 EP disclosed
WO-2007082840-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HRH3, HRH4, HRH1 ATM 3609/4885DRD2 1307/4885ADRA1D 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.